Document Detail


PKC inhibitor Go6976 induces mitosis and enhances doxorubicin-paclitaxel cytotoxicity in urinary bladder carcinoma cells.
MedLine Citation:
PMID:  17320279     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Protein kinase C (PKC) alpha/betaI isoenzyme inhibitor Go6976 has been suggested to be a G2 checkpoint abrogator by direct Chk1 inhibition. In the present study, we demonstrate that Go6976 induces mitosis in doxorubicin treated G2-arrested 5637 urinary bladder transitional cell carcinoma cells and interestingly also in non-synchronized 5637 cells. Importantly, the results demonstrated that both doxorubicin treated and non-synchronized cancer cells are forced to mitosis by Go6976. However, part of the cells avoid the death in mitosis and continue in the cell cycle which may increase the probability of genomic instability. Cytotoxicity of Go6976 alone and in combination with chemotherapeutic agents was further studied. Go6976 treatment alone induced apoptotic cell death. Cytostatic doxorubicin pre-treatment induced G2 arrest and inhibited the cytotoxic effects of mitosis specific drug paclitaxel. Cytotoxicities of doxorubicin-paclitaxel and doxorubicin-Go6976 sequences could be markedly enhanced by combining Go6976 with paclitaxel after doxorubicin pre-treatment. In doxorubicin-Go6976+paclitaxel sequence, paclitaxel arrested the cells to mitosis and unfavourable progression of the cell cycle was inhibited. Analyzes of the molecular mechanisms underlying Go6976 induced mitosis showed that PKC inhibiting concentrations of Go6976 induced cdc2 activation concentration-dependently in non-synchronized and in DNA damaged cells. Simultaneously, Chk1/2 became deactivated and cdc25C activated in DNA damaged cells, indicating regulatory events upstream. In non-synchronized cells, activation of cdc25C, but not Chk1/2, was observed, suggesting inactivation of c-TAK1. The results of the current study suggest that Go6976 has a synergistic cytotoxic effect when combined with doxorubicin and paclitaxel.
Authors:
Vesa Aaltonen; Jussi Koivunen; Matti Laato; Juha Peltonen
Related Documents :
8219109 - Interplay between differentiation and cell cycle arrest at g1 in phorbol diester-treate...
2549409 - Comparison of gamma-radiation-induced accumulation of ataxia telangiectasia and control...
853059 - Continued initiation of dna synthesis in arginine-deprived chinese hamster ovary cells.
2634429 - Cytotoxicity by tumor necrosis factor is linked with the cell cycle but does not requir...
18388949 - Cell cycle synchronization of animal cells and nuclei by centrifugal elutriation.
10577389 - Induction of s phase by g1 regulatory factors.
14742249 - Differential expression of thromboxane synthase in prostate carcinoma: role in tumor ce...
21531789 - Silencing of frataxin gene expression triggers p53-dependent apoptosis in human neuron-...
24607589 - Bisphosphonate prodrugs: synthesis and biological evaluation in huh7 hepatocarcinoma ce...
Publication Detail:
Type:  Journal Article; Research Support, Non-U.S. Gov't     Date:  2007-02-22
Journal Detail:
Title:  Cancer letters     Volume:  253     ISSN:  0304-3835     ISO Abbreviation:  Cancer Lett.     Publication Date:  2007 Aug 
Date Detail:
Created Date:  2007-06-11     Completed Date:  2007-08-21     Revised Date:  2012-06-25    
Medline Journal Info:
Nlm Unique ID:  7600053     Medline TA:  Cancer Lett     Country:  Ireland    
Other Details:
Languages:  eng     Pagination:  97-107     Citation Subset:  IM    
Affiliation:
Department of Anatomy and Cell Biology, University of Oulu, Oulu, Finland.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Carbazoles / pharmacology*
Cell Death / drug effects
DNA Damage
Doxorubicin / pharmacology*
Enzyme Inhibitors / pharmacology
G2 Phase
Humans
Indoles / pharmacology*
Mitosis / drug effects*
Models, Biological
Paclitaxel / pharmacology*
Protein Kinase C-alpha / antagonists & inhibitors,  physiology*
Tumor Cells, Cultured
Urinary Bladder Neoplasms / pathology*
Chemical
Reg. No./Substance:
0/Carbazoles; 0/Enzyme Inhibitors; 0/Indoles; 136194-77-9/Go 6976; 23214-92-8/Doxorubicin; 33069-62-4/Paclitaxel; EC 2.7.11.13/PRKCA protein, human; EC 2.7.11.13/Protein Kinase C-alpha

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Potential target antigens for immunotherapy in human pancreatic cancer.
Next Document:  Genome-wide expression analysis using microarray identified complex signaling pathways modulated by ...